Genome & Company

Research Genome & Company (314130.KQ) on Bullrun: market cap KRW 212.56B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is KRW 212.56B.

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-10-18KRW 212.56Bn/an/an/a

Dividend history

About Genome & Company

Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea, Asia, Europe, South America, North America, and internationally. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The company also develops GEN-501 targeting the non-responders of Dupilumab drugs with atopic skin diseases;

Related stock research

South Korea stocks South Korea Healthcare stocks A-Z stock index

Other Healthcare stocks

ORIENT BIO Inc. (002630.KS) GC Corp. (005250.KS) Pharmicell Co., Ltd. (005690.KS) Kanaph Therapeutics Inc. (0082N0.KQ) Samik Pharmaceutical Company LTD. (014950.KQ) HLB Co., Ltd. (028300) Mgen Solutions Co., Ltd. (032790.KQ) Daesung Microbiological Labs. Co., Ltd. (036480.KQ) Seoulin Bioscience Co.,Ltd. (038070.KQ) Hyundai Bioscience Co., Ltd. (048410.KQ) iNtRON Biotechnology, Inc. (048530.KQ) Synergy Innovation Co., Ltd. (048870.KQ)

Frequently asked questions

What is Genome & Company's market cap?

Genome & Company's market capitalization is KRW 212.56B.

What does Genome & Company do?

Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea, Asia, Europe, South America, North America, and internationally. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities.